학술논문
Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia.
Document Type
Article
Author
Source
Subject
*CARDIOVASCULAR diseases risk factors
*NILOTINIB
*CHRONIC myeloid leukemia
*CARDIOVASCULAR diseases
*PATIENTS
*RISK assessment
*
*
*
*
*
Language
ISSN
0887-6924
Abstract
The article discusses the use of the 2012 European cardiovascular diseases (CVD) risk assessment model aimed at identifying high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia (CML). It outlines the impressive performance of the European CVD risk assessment system to identify nilotinib-treated CML patients. Prevention approaches in high/very high CVD risk patients are also offered.